2nd Quarter - Report
THE MCMANUS GROUP for AMGEN
Firm
Client
Income
$60,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement under Medicare Part B drugs. Policies related to the Most Favored Nation Drug Pricing Model
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.